Cancer Chemotherapy and Pharmacology

, Volume 31, Issue 6, pp 445–448 | Cite as

Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial

  • Takashi Yoshida
  • Makoto Ogawa
  • Kazuo Ota
  • Yutaka Yoshida
  • Akira Wakui
  • Masao Oguro
  • Yutaka Ariyoshi
  • Masami Hirano
  • Ikurou Kimura
  • Tamotsu Matsuda
Original Articles NK313, Malignant Lymphomas, Phase II Study
  • 9 Downloads

Summary

Liblomycin (NK313) is a bleomycin analog that has proved to be associated with less pulmonary toxicity and with more potent antitumor activity than bleomycin in animal tumors. In a phase I study, pulmonary toxicity was not observed, whereas myelosuppression was the dose-limiting factor. The maximum tolerated dose was 140 mg/m2 given once a week for 4 weeks. In the present phase II study, patients with malignant lymphomas received liblomycin at 80 or 100 mg/m2 by intravenous infusion over 15 min once a week for 4 weeks. A total of 39 patients were entered, and 31 [4 with Hodgkin's disease (HD) and 27 with non-Hodgkin's lymphoma (NHL)] were evaluable. The median age of the patients was 52 years (range, 22–74 years), and their performance status ranged from 0 to 3. In all, 28 of the patients had a history of intensive anticancer chemotherapy. Responses were evaluated according to WHO criteria. We obtained 1 complete remission and 9 partial remissions (PRs), for an overall response rate of 37%, in the 27 patients with NHL, whereas 1 PR was achieved in the 4 patients with HD. In all, 9 PRs (32.1%) were obtained in patients who has been exposed to prior chemotherapy, including 4 PRs (33.3%) in 12 patients who had previously been treated with bleomycin. Myelosuppression and nausea and vomting were the major toxicities, which occurred in about 50% of the patients, and myelosuppression was severe in two patients treated at a dose of 100 mg/m2. We concluded that liblomycin demonstrated significant antitumor activity against malignant lymphomas.

Keywords

Lymphoma Complete Remission Antitumor Activity Bleomycin Malignant Lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ariyoshi Y, Ota K, Suzuki A, Tamura M, Hasegawa K, Yoshida S, Honma T, Majima M, Niitani H, Ogawa M, Fukuoka M, Furuse K, Kimura I, Ohnoshi T, Ogura T, Shimaoka K (1989) Phase I study of liblomycin (NK313). Proc Am Soc Clin Oncol 8:287Google Scholar
  2. 2.
    Bonadonna G, Santoro A (1982) ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 9:21Google Scholar
  3. 3.
    Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large-cell Lymphoma. Ann Intern Med 102:596Google Scholar
  4. 4.
    Koiso K, Niijima T (1981) Chemotherapy of advanced prostatic cancer with peplomycin. Prostate [Suppl] 1:103Google Scholar
  5. 5.
    Miller AB, Hoogstraten B, Staqet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207Google Scholar
  6. 6.
    Skarin AT, Canellos GP (1985) BACOP and related studies in non-Hodgkin's lymphoma: bleomycin chemotherapy. Academic Press, Orlando, p 187Google Scholar
  7. 7.
    Takahashi K, Ekimoto H, Minamide S, Nishikawa K, Kuramochi H, Motegi A, Nakatani T, Takita T, Takeuchi T, Umezawa H (1987) Liblomycin, a new analogue of bleomycin. Cancer Treat Rev 14:169Google Scholar
  8. 8.
    Word Health Organization (1979) Handbook for reporting the results of cancer treatment. Offset publication 48. WHO GenevaGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Takashi Yoshida
    • 1
  • Makoto Ogawa
    • 2
  • Kazuo Ota
    • 3
  • Yutaka Yoshida
    • 4
  • Akira Wakui
    • 5
  • Masao Oguro
    • 6
  • Yutaka Ariyoshi
    • 7
  • Masami Hirano
    • 8
  • Ikurou Kimura
    • 9
  • Tamotsu Matsuda
    • 1
  1. 1.The Third Department of Internal MedicineKanazawa University School of MedicineKanazawaJapan
  2. 2.Cancer Chemotherapy CenterJapanese Foundation for Cancer ResearchJapan
  3. 3.Nagoya Memorial HospitalNagoyaJapan
  4. 4.First Department of Internal MedicineHirosaki University School of MedicineHirosakiJapan
  5. 5.Clinical Cancer Chemotherapy, The Research Institute for Tuberculosis and CancerTohoku UniversitySendaiJapan
  6. 6.Chiba Cancer Center HospitalChibaJapan
  7. 7.Aichi Cancer Center HospitalAichiJapan
  8. 8.Internal MedicineFujita Health University School of MedicineAichiJapan
  9. 9.Second Department of Internal MedicineOkayama University Medical SchoolOkayamaJapan

Personalised recommendations